![]() |
市场调查报告书
商品编码
1764891
2031年北美青光眼治疗市场预测 - 区域分析 - 按药物类别、适应症和配销通路North America Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel |
2023 年北美青光眼治疗市场价值为 26.3452 亿美元,预计到 2031 年将达到 34.2164 亿美元;预计 2023 年至 2031 年的复合年增长率为 3.3%。
青光眼发生率不断上升推动北美青光眼治疗市场
青光眼是一种因视神经受损引起的眼部疾病,最终可能导致完全失明。青光眼患者可能会逐渐经历神经组织损失,如果不及时治疗,会导致视力下降或失明。全球青光眼病例正在显着增加。根据青光眼研究基金会的数据,到 2040 年,全球预计将有 2,200 万人因青光眼而失明。此外,根据世界卫生组织的数据,青光眼是全球主要的失明原因,影响超过 6,000 万人,导致约 450 万人失明。根据 2021 年 1 月发表在《视觉与眼科学研究协会》(ARVO)杂誌上的一篇文章的估计,到 2030 年底、2040 年底和 2050 年底,墨西哥患有青光眼的人数将分别达到 250 万人、300 万人和 340 万人。随着全球青光眼病例数量的不断增加,对青光眼治疗的需求也日益增长。用于治疗青光眼的医疗和外科手术主要着重于降低眼压 (IOP)。前列腺素类似物是广泛推荐的药物之一,可透过促进眼球引流来有效降低眼压。由于其疗效显着且不良反应有限,这些产品已成为青光眼治疗的主流方案。
北美洲青光眼治疗市场概况
根据美国人口参考局 2019 年的数据,到 2060 年,美国 65 岁及以上人口的数量预计将从 2018 年的 5,200 万(占总人口的 16%)翻一番,增至近 9,500 万人(占总人口的 23%)。美国眼科学会 2019 年进行的一项研究表明,到 2050 年,美国 70-75 岁人群估计将有近 732 万人患有原发性开角型青光眼 (POAG)。因此,美国青光眼治疗市场的成长主要受眼部疾病盛行率上升的推动,尤其是在老年人口中。美国占北美青光眼治疗市场的最大份额。
市场参与者采用的各种有机和无机成长策略也为美国青光眼治疗市场的发展做出了显着贡献。以下列举了一些此类成长策略。
2023年10月,Stuart Therapeutics与Glaukos签署了Stuart Therapeutics ST-113候选药物的授权协议,该药物旨在保护青光眼患者的神经。 2022年8月,爱尔康收购了Aerie Pharmaceuticals, Inc.。这项交易证实了爱尔康对眼科药物领域的承诺,并有望透过增加更广泛的药物研发能力来增强其现有的商业专长,从而最大限度地提升其多元化产品组合的价值。北美青光眼治疗市场收入及预测(2031年)(百万美元)
北美青光眼治疗市场细分
北美青光眼治疗市场按药物类别、适应症、配销通路和国家分类。
依药物类别,北美青光眼治疗市场细分为β受体阻断剂、α肾上腺素激动剂、前列腺素类似物、碳酸酐酶抑制剂、复方药物及其他。前列腺素类似物在2023年占据了最大的市场。
根据适应症,北美青光眼治疗市场分为开角型青光眼、闭角型青光眼和其他类型。 2023年,开角型青光眼占了最大的市场。
按配销通路划分,北美青光眼治疗市场分为医院药房、零售药房和线上药房。 2023年,医院药局占了最大的市场份额。
按国家/地区划分,北美青光眼治疗市场分为美国、加拿大和墨西哥。 2023年,美国占据了北美青光眼治疗市场的主导地位。
Alcon AG、AbbVie Inc、Bausch & Lomb Inc、Fera Pharmaceuticals, LLC、Viatris Inc、Novartis AG、Sun Pharmaceutical Industries Ltd、Teva Pharmaceuticals Industries Ltd、Thea Pharma Inc 和 Santen Pharmaceutical Co., Ltd. 是北美青光眼治疗市场领先的公司。
The North America glaucoma therapeutics market was valued at US$ 2,634.52 million in 2023 and is expected to reach US$ 3,421.64 million by 2031; it is estimated to register a CAGR of 3.3% from 2023 to 2031.
Mounting Incidence of Glaucoma Disease Fuels North America Glaucoma Therapeutics Market
Glaucoma is an eye disorder caused due to the damaged optic nerve, which can eventually lead to total blindness. Glaucoma patients may experience a gradual loss of nerve tissue, resulting in vision impairment or blindness if left untreated. Glaucoma cases are increasing significantly across the world. As per the Glaucoma Research Foundation, an estimated 22 million people worldwide would attain blindness due to glaucoma by 2040. Further, Glaucoma is a leading cause of blindness worldwide, affecting over 60 million people and leading to approximately 4.5 million cases of blindness, according to the World Health Organization. According to estimates provided in an article published in the Association for Research in Vision and Ophthalmology (ARVO) Journal in January 2021, the number of people suffering from glaucoma in Mexico would reach 2.5 million, 3 million, and 3.4 million by the end of 2030, 2040, and 2050, respectively. The demand for glaucoma treatments is increasing with the rising number of glaucoma cases in the global population. Medical and surgical procedures meant to manage this disease focus on lowering intraocular pressure (IOP). Prostaglandin analogs are among the drugs widely recommended for effectively reducing IOP by promoting better drainage from the eye. These products have been mainstream glaucoma treatment due to their efficacy and limited adverse effects.
North America Glaucoma Therapeutics Market Overview
As per the Population Reference Bureau 2019, the number of individuals aged 65 and above in the US is estimated to double from 52 million (16% of the total population) in 2018 to nearly 95 million (23% of the total population) by 2060. A study conducted by the American Academy of Ophthalmology in 2019 states that nearly 7.32 million people aged 70-75 is estimated to be affected by primary open-angle glaucoma (POAG) in the US by 2050. Thus, the glaucoma therapeutics market growth in the US is primarily driven by the increasing prevalence of eye diseases, especially in the geriatric population. The US accounts for the largest share of the glaucoma therapeutics market in North America.
Various organic and inorganic growth strategies adopted by market players also contribute notably to the glaucoma therapeutics market progress in the US. A few of such growth strategies are mentioned below.
In October 2023, Stuart Therapeutics and Glaukos signed a license agreement for Stuart Therapeutics' ST-113 drug candidate designed for neuroprotection in glaucoma. In August 2022, Alcon acquired Aerie Pharmaceuticals, Inc. This transaction confirms Alcon's commitment to the ophthalmic pharmaceutical space, and it is expected to enhance its existing commercial expertise by adding broader pharmaceutical R&D capabilities, thereby maximizing the value of its diversified portfolio. North America Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)
North America Glaucoma Therapeutics Market Segmentation
The North America glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.
Based on drug class, the North America glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.
In terms of indication, the North America glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.
By distribution channel, the North America glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.
By country, the North America glaucoma therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the North America glaucoma therapeutics market share in 2023.
Alcon AG, AbbVie Inc, Bausch & Lomb Inc, Fera Pharmaceuticals, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the North America glaucoma therapeutics market.